A phase 2, placebo-controlled, 28-day study of PTI-428 in patients with cystic fibrosis with at least one F508del mutation
Latest Information Update: 02 Jan 2023
At a glance
- Drugs Dirocaftor (Primary) ; Nesolicaftor (Primary) ; Posenacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kineta; Proteostasis Therapeutics; Yumanity Therapeutics
Most Recent Events
- 19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
- 17 Dec 2019 Results presened in a Proteostasis Therapeutics Media Release.
- 06 Nov 2019 According to a Proteostasis Therapeutics media release, due to rapid enrollment from centers in the United States, Canada, Western Europe, and New Zealand, data from the study are now expected in the fourth quarter of 2019 instead of the first quarter of 2020.